Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older.
• People who have been newly diagnosed with liver cancer (hepatocellular carcinoma) that has been confirmed by biopsy or imaging, and who have not yet received any treatment for it. At least one measurable tumour must be present. A previous liver cancer that was treated by surgery or radiation at least 2 years before the current diagnosis may still be acceptable.
• People whose liver cancer has been assessed as locally advanced and not able to be removed by surgery.
• People with a liver cirrhosis severity score (Child-Pugh score) of A5 or A6, indicating relatively preserved liver function.
• People who are generally well enough to carry out light daily activities, as measured by a standard performance scale (ECOG score of 0 or 1).
• People whose blood counts and organ function meet specific minimum levels — including adequate levels of white blood cells, platelets, red blood cells, liver enzymes, and kidney function (confirm specific values with the trial site).
• People who are sexually active with a partner who could become pregnant must agree to use an effective form of contraception throughout the trial, as the treatment may be harmful to a developing baby.
• People who are able to understand the trial and are willing to sign a written consent form agreeing to take part.
• People of any race, ethnic group, or sexual orientation.
• People who are able to swallow oral (by mouth) medication.

Who may not be able to join:

• People with a more severe level of liver cirrhosis (Child-Pugh B or C score).
• People who are pregnant or currently breastfeeding.
• People with other serious illnesses that could affect how well the trial team can monitor them, or that could put them at added risk.
• People with any serious medical condition that the trial doctor considers makes them unsuitable, including uncontrolled or untreated viral infections such as HIV, hepatitis B, or hepatitis C.
• People who are already taking part in another interventional clinical trial.
• People with active tuberculosis.
• People who have had a significant heart or stroke-related event (such as a heart attack or stroke) within the 3 months before starting the trial, or who have an unstable heart rhythm or unstable chest pain.
• People with a history of severe allergic reactions to certain types of laboratory-made antibody treatments (confirm with trial site).
• People with a known allergy to the study drugs atezolizumab or bevacizumab, or to any of their ingredients (confirm with trial site).
• People diagnosed with certain rare subtypes of liver cancer, including fibrolamellar HCC, sarcomatoid HCC, or a mixed type involving both liver cancer and bile duct cancer.
• People with severe, uncontrolled pain caused by their cancer. People who use pain medication must be on a stable dose before joining.
• People who have had major surgery, an open biopsy, or a serious physical injury within 28 days before starting the trial.
• People who have cancer that has spread to the brain or spinal cord and is causing symptoms, has not been treated, or is continuing to grow.
• People with active, untreated enlarged veins in the food pipe or stomach (varices) rated at grade 2 or 3. People whose varices have been treated and brought down to grade 1 or lower may still be considered.
• People who are already taking the medication memantine for any reason before enrolling.

Important: Always verify eligibility with the trial site directly before applying.